Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone

Tidhar Turgeman, Yosey Hagai, Kyla Huebner, Davinder S. Jassal, Judy E. Anderson, Olga Genin, Arnon Nagler, Orna Halevy, Mark Pines*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Abstract

Fibrosis is a known feature of dystrophic muscles, particularly the diaphragm, in the mdx mouse. In this study we evaluated the effect of halofuginone, a collagen synthesis inhibitor, on collagen synthesis in various muscles of young wild-type (C57/BL/6J) and mdx mice. Halofuginone prevented the age-dependent increase in collagen synthesis in the diaphragms of mdx with no effect on wild-type mice (n = 5 for each time point). This was associated with a decrease in the degenerated areas and number of central nuclei. Halofuginone also inhibited collagen synthesis in cardiac muscle. Moreover, enhanced motor coordination, balance and improved cardiac muscle function were observed implying reduced muscle injury. Halofuginone inhibited Smad3 phosphorylation downstream of TGFβ in the diaphragm and cardiac muscles, in C2 cell line and in primary mouse myoblast cultures representing various muscular dystrophies. We suggest that via its effect on Smad3 phosphorylation, halofuginone inhibits muscle fibrosis and improves cardiac and skeletal muscle functions in mdx mice.

Original languageEnglish
Pages (from-to)857-868
Number of pages12
JournalNeuromuscular Disorders
Volume18
Issue number11
DOIs
StatePublished - Nov 2008

Keywords

  • Collagen
  • Diaphragm
  • Echocardiography
  • Muscular dystrophy
  • Smad3
  • TGF-beta

Fingerprint

Dive into the research topics of 'Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone'. Together they form a unique fingerprint.

Cite this